Skip to content

Intravenous Immunoglobulin decrease rate of Immunologic Abortion

Low-Dose Intravenous Immunoglobulin decrease rate of Immunologic Abortion; a clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015021220993N2
Enrollment
50
Registered
2015-03-11
Start date
2007-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion. Supervision of pregnancy with history of abortive outcome

Interventions

Intervention 1: Aspirin (80 mg) was administered daily to the control group. Intervention 2: the study group 5 g IVIG was initiated within 2 weeks prior to attempted conception. After conception occur
Treatment - Drugs
Aspirin (80 mg) was administered daily to the control group
the study group 5 g IVIG was initiated within 2 weeks prior to attempted conception. After conception occurred, IVIG was given every 4 weeks for up to 32 weeks of gestation. IVIG was administered in h

Sponsors

Vice chancellor of research in Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: women with at least two abortions that had taken place naturally or with assisted reproductive techniques (ART) and who had at least one positive immunologic test for anti-cardiolipin; anti-phospholipid antibodies;anti-thyroid antibody; anti-nuclear antibody;Anti-sperm antibody. Exclusion criteria: anatomical problems; infections; hormonal factors contributing to recurrent abortion and parental factors were excluded.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Neonate. Timepoint: 9 month. Method of measurement: Delivery.

Secondary

MeasureTime frame
Abortion. Timepoint: Each time after intervention. Method of measurement: exposing symptoms of abortion.;Premature birth. Timepoint: Each time after intervention. Method of measurement: exposing symptoms of premature birth.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmajid jafari

Mashhad University of Medical Sciences

jafarim912@mums.ac.ir+98 51 3801 2770

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026